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Abstract
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Background and Aims—Adiponectin, an adipose-secreted protein that has been linked to
insulin sensitivity, plasma lipids, and inflammatory patterns, is an established biomarker for
metabolic health. Despite clinical relevance and high heritability, the determinants of plasma
adiponectin levels remain poorly understood.
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Methods and Results—We conducted the first epigenome-wide cross-sectional study of
adiponectin levels using methylation data on 368,051 cytosine-phosphate-guanine (CpG) sites in
CD4+ T-cells from the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN, n= 991).
We fit linear mixed models, adjusting for age, sex, study site, T-cell purity, and family. We have
identified a positive association (regression coefficient ± SE= 0.01 ± 0.001, P=3.4x10−13) between
plasma adiponectin levels and methylation of a CpG site in CPT1A, a key player in fatty acid
metabolism. The association was replicated (n=474, P=0.0009) in whole blood samples from the
Amish participants of the Heredity and Phenotype Intervention (HAPI) Heart Study as well as
White (n=592, P=0.0005) but not Black (n=243, P=0.18) participants of the Bogalusa Heart Study
(BHS). The association remained significant upon adjusting for BMI and smoking in GOLDN and
HAPI but not BHS. We also identified associations between methylation loci in RNF145 and
UFM1 and plasma adiponectin in GOLDN and White BHS participants, although the association
was not robust to adjustment for BMI or smoking.
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Conclusion—We have identified and replicated associations between several biologically
plausible loci and plasma adiponectin. These findings support the importance of epigenetic
processes in metabolic traits, laying the groundwork for future translational applications.
Keywords
epigenetics; methylation; adiponectin; epidemiology

Introduction
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Adiponectin is an adipocyte-derived secretory protein with generally positive, multi-pronged
effects on metabolic health (1). Levels of circulating adiponectin in the plasma are heritable
(h2=55.1%) (2) and widely used as a biomarker for cardiovascular and metabolic risk.
Despite clinical relevance and high heritability, the genetic determinants of plasma
adiponectin remain poorly understood, with the known genetic polymorphisms accounting
for only a modest fraction of inter-individual variability (3). An emerging body of evidence
suggests that epigenetic changes such as DNA methylation may contribute to the “missing
heritability” and merit further evaluation as risk factors for metabolic disease (4). However,
prior epigenetic investigations into the adiponectin pathway were largely limited in scope
and/or sample size, focusing on candidate regions rather than epigenome-wide variation.
The advent of high-throughput array-based methods has enabled a comprehensive approach
to quantifying epigenetic variation, promising new insights into the relationship between
DNA methylation and complex traits such as circulating adiponectin.

Author Manuscript

Using DNA isolated from CD4+ T-cells from 991 European American participants of the
Genetics of Lipid Lowering Drugs and Diet Network (GOLDN), we have performed the first
cross-sectional epigenome-wide study (EWAS) of plasma adiponectin. We subsequently
replicated our top finding in two external populations, using whole blood samples from the
Heredity and Phenotype Interaction (HAPI) Heart Study (n=474) and the Bogalusa Heart
Study (BHS, n=835). We further conducted sensitivity analyses to account for the potential
role of obesity, smoking, and alcohol in the relationship between DNA methylation and
circulating adiponectin. Finally, we have examined methylation variation in regions reported
to be associated with circulating adiponectin in prior genetic studies to provide a more
comprehensive view of heritable determinants of cardiometabolic health.

Methods
Study Populations

Author Manuscript

Discovery—The GOLDN study population, previously described in detail (5–8), was
comprised of European American families with at least two siblings, recruited from the
participants of the National Heart, Lung, and Blood Institute Family Heart Study in
Minneapolis and Salt Lake City. Before each study visit, participants abstained from eating
for 8 hours, drinking alcohol for 24 hours, and using other lipid-lowering medications for 4
weeks. The Institutional Review Boards at the University of Minnesota, University of Utah,
and Tufts University/New England Medical Center approved the study protocol, and all
participants provided informed consent.
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Replication—BHS is a long-term community-based study of cardiovascular risk factors in
a biracial (Black/White) rural community in Louisiana (11). Participants provided informed
consent, while the study design and procedures as well as consent forms were approved by
Institutional Review Boards from Louisiana State University and Tulane University Medical
Center.
The HAPI Heart Study (n=868) is a community-based study of cardiovascular risk carried
out in the Amish community from Lancaster County, Pennsylvania (9). Virtually all
participants have descended from approximately 200 founders of the Old Order Amish
community (10). The study was approved by the appropriate Institutional Review Boards
and monitored by an external Data Safety Monitoring Board.
DNA Methylation Measurements

Author Manuscript
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GOLDN—Procedures for quantifying DNA methylation in GOLDN have been extensively
described in previous publications (12, 13). Briefly, we restricted our analyses to CD4+ Tcells, isolated from peripheral blood frozen buffy coat samples, to reduce confounding by
cell type. Upon isolating DNA using the DNeasy Kits (Qiagen, Venlo, Netherlands), we
used the Infinium Human Methylation 450 Beadchip (Illumina, San Diego, CA) to measure
genome-wide DNA methylation (12). Subsequently, we estimated β scores, defined as the
proportion of total signal from the methylation-specific probe or color channel, and
detection p-values, defined as the probability that the total intensity for a given probe falls
within the background signal intensity, using the GenomeStudio software provided by the
manufacturer. For reasons of quality control, we did not analyze any β scores with an
associated detection p-value greater than 0.01, samples with more than 1.5% missing data
points across ~470,000 autosomal CpGs, or probes where 10% of samples or more failed to
yield adequate intensity (12). After filtering, we normalized the resulting β scores using the
ComBat package for R software in non-parametric mode to account for batch effects (14).
Normalization for probes from the Infinium I and II chemistries was done separately, with
subsequent adjustment of the Infinium II scores as previously described (12). As the final
quality control step, we identified and removed cross-reactive probes (12) and CpGs sites
with SNPs on the probe as reported by Barfield et al (15). A total of 991 samples and
368,051 CpG sites remained in the analysis.
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HAPI Heart Study—For the replication study, we extracted DNA from whole blood
collected in acid citrate dextrose tubes (BD, Franklin Lakes, NJ) using the Gentra Puregene
kit (Qiagen, Venlo, Netherlands). According to the manufacturer’s protocol, we treated 1μg
of genomic DNA with bisulfite using the Epitect Fast 96 DNA bisulfite kit (Qiagen, Venlo,
Netherlands). We obtained PyroMark CpG assays (Qiagen, Venlo, Netherlands) to quantify
methylation on the top finding from GOLDN, located at CpG site cg00574958. To that end,
we amplified 1 μl of bisulfite converted DNA using the PyroMark PCR kit (Qiagen, Venlo,
Netherlands) with the supplied parameters. We determined PCR success by gel
electrophoresis in 1.75% agarose gel. We performed pyrosequencing on 10μl of PCR
product using sequencing primer GTTGGTTTGGGGATTATTA and the
GTATTYGTAGTTGGTTTTTTGGATTGGTTTTG sequence to analyze. We successfully
pyrosequenced a total of 726 samples. Of those, 543 samples had PCR reactions carried out
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in duplicate on two different machines, with the remaining 183 samples analyzed only on a
single machine. The methylation measures utilized in the analysis correspond to samples
with duplicate measures, using the average of the two methylation values. We additionally
assessed the reproducibility of methylation measurements in the paired samples and
removed observations for whom the coefficient of variation exceeded 20%, leaving 474
participants for the final analysis.
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BHS—We extracted genomic DNA from 835 whole blood samples using the PureLink Pro
96 Genomic DNA Kit (LifeTechnology, CA) following the manufacturer’s instructions.
Identically to GOLDN, we used the Infinium HumanMethylation450 BeadChip to quantify
DNA methylation. All the DNA samples were processed at the Microarray Core Facility,
University of Texas Southwestern Medical Center at Dallas, Texas. The image was acquired
with HiScan scanner and analyzed with GenomeStudio software. The call rates for all
samples across all CpG sites exceeded 99.8%. We used the latest version (1.2) of the
Illumina Human Methylation 450k annotation in the current study to get the corresponding
location information. Similarly to GOLDN, we converted DNA methylation levels at CpG
sites into β scores (analogous to the proportion of DNA methylated), a continuous variable
between 0 (unmethylated) and 1 (fully methylated). We normalized the data using the R
package watermelon (16). For correction of systematic technical biases in the 450K assay,
we normalized β scores using the dasen function, in which type I and type II intensities and
methylated and unmethylated intensities are quantile-normalized separately after
backgrounds equalization of type I and type II probes. Based on bead count and detection pvalues, we set the following thresholds for removal: 1) samples having 1% of CpG sites with
a detection p-value greater than 0.05; 2) probes having 5% of samples with a detection pvalue greater than 0.05; 3) probes with bead count less than 3 in 5% of samples.
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Adiponectin Measurements
As described in a prior GOLDN publication (17), we assayed plasma adiponectin using an
ELISA kit from R&D Systems (Minneapolis, MN). We centrifuged all samples at 2000 x g
for 15 minutes at 4 degrees Celsius within 20 minutes of collection, stored them frozen at
−70 degrees C, and analyzed at the same time to eliminate batch effects. The reliability
coefficient was estimated at 0.95 (17). Both HAPI Heart Study and BHS measured
adiponectin levels using a commercial radioimmunoassay kit (Linco Research, St Charles,
MO). Adiponectin data were available on 474 HAPI Heart participants and 835 BHS
participants with DNA methylation data that passed quality control exclusions as described
above.

Author Manuscript

Statistical Methods
The statistical methods for discovery and replication are summarized in Supplemental Table
1. Specifically, in all three populations we used linear mixed models to evaluate the
association between plasma adiponectin (exposure) and DNA methylation β scores
(outcome). To limit the undue influence of the skewed the adiponectin distribution on the
regression coefficient estimates, we have ln-transformed it in all three populations.
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Discovery—In GOLDN, we used linear mixed models to test for associations between
methylation scores at each CpG site and ln-transformed plasma adiponectin adjusting for
age, sex, study site, and the first 4 principal components generated to capture T-cell purity as
fixed effects, and family as a random effect. We conducted sensitivity analyses additionally
adjusting for body mass index (BMI), smoking, and alcohol to account for potential
confounding. We constructed Manhattan plots to visualize the results.

Author Manuscript

Replication—We sought replication of all top hits (false discovery rate (FDR) < 0.2) from
GOLDN in the BHS cohort, which had extant methylation data available. Because the HAPI
Heart cohort did not have array measurements of methylation and instead performed de novo
pyrosequencing, we limited that replication effort to the top GOLDN CpG (FDR < 0.05). In
BHS, we fit linear mixed models adjusted for age, sex, and white blood cell differential cell
counts (CD8T, CD4T, NK, B cells, monocytes, and granulocytes) as fixed effects and batch
as a random effect. BHS analyses were stratified by race. The replication analysis in BHS
used α=0.05/number of CpGs with FDR < 0.2 in GOLDN= 0.05/34= 0.001. For the
GOLDN hits that successfully replicated in at least one racial subgroup of BHS, we fit
additional models including 1) BMI and 2) smoking and alcohol intake as sensitivity
analyses.
In HAPI Heart, the models adjusted for age, sex, and batch as fixed effects as well as
accounted for the family structure by including the relationship matrix as a random effect.
We fit additional models with BMI and smoking as covariates to examine robustness of the
finding. Because only one CpG locus was tested in HAPI Heart, this replication analysis
used α=0.05 as the significance threshold.
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Although the discovery analysis did not include batch as a covariate because its effects were
removed during the normalization phase using ComBat, we did account for batch in
statistical models fit to the replication cohorts. Results from all three studies were metaanalyzed using Fisher’s method (18), which makes no assumptions about individual effect
sizes, as the estimates of effect were not directly comparable due to differences in cell types
and modeling approaches.

Author Manuscript

Integration—In light of the evidence linking sequence variation to epigenetic patterns, we
have attempted integrating signals from prior genome-wide linkage and association studies
of adiponectin in GOLDN with the epigenetic data. Specifically, we have performed look-up
of methylation variants located in or near (+/−50 bp) the genes previously identified as
implicated in adiponectin homeostasis in our study population: ADIPOQ, CDH13,
IL22RA1, IL28RA, PCSK5, SCUBE1, and TMEM18, as well as intergenic variants on
chromosomes 12 and 20 (7, 17). We also interrogated methylation in the following
adiponectin-related genes identified in two or more populations in the GWAS catalog:
ARL15, CMIP, FER, GPR109A, and PEPD (http://www.ebi.ac.uk/gwas/search?
query=Adiponectinlevels). To conduct the lookup, we obtained regression coefficients and
P-values for each CpG located in or near (+/−50 bp) the aforementioned candidate genes in
the epigenome-wide study results from the discovery cohort (GOLDN).
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Results
Table 1 summarizes the general characteristics of the study populations. Mean adiponectin
concentrations were the highest among Amish participants and lowest among Black BHS
participants; the inverse pattern was observed for BMI. On average, study participants were
overweight but not obese.
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We identified one locus in the first intron of CPT1A that was methylated in a direct
correlation with plasma adiponectin (i.e. individuals with higher plasma adiponectin levels
had higher methylation scores at this CpG site). In addition to the CPT1A locus, there were
suggestive associations (FDR < 0.20) for CpG sites in FAM166B, SORL1, RNF145, UFM1,
and ASAM genes, among others. Table 2 shows the location, strength of association, and
annotation for the top hits while Figure 1 summarizes epigenome-wide results. Upon
adjustment for BMI (Table 3), the association with the CPT1A locus diminished but
remained statistically significant; however, the association estimates for other loci weakened
substantially, yielding only two CpGs with FDR < 0.20. In the models that adjusted for
current smoking status or alcohol intake (Supplemental Table 2), the estimate of effect did
not appreciably change compared with the baseline model.
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Out of the 34 CpGs that were tested for replication in BHS, only 3 reached statistical
significance in the White subset upon adjusting for multiple testing: cg00574958 in CPT1A,
cg19750657 in UFM1, and cg26403843 in RNF145 (Table 2), whereas none were
significant in the smaller Black subsample. Adjustment for either BMI or smoking
attenuated the observed association with both loci in the BHS White participants, rendering
them no longer statistically significant (cg00574958: P= 0.14 and 0.15, cg19750657: P=
0.01 and 0.02, cg26403843: P=0.005 and 0.006 when adjusted for BMI and smoking plus
alcohol, respectively).
Subsequently, the association with CPT1A locus was confirmed in the HAPI Heart study
(Table 4). In the 474 participants of the HAPI Heart study, ln-transformed adiponectin levels
were significantly and positively associated with cg00574958 methylation, similarly to
GOLDN and BHS. The difference in the magnitude of the regression coefficients between
HAPI Heart analyses and the other two cohorts could potentially be explained by different
methylation measuring techniques (array vs. pyrosequencing). In HAPI Heart participants,
the association diminished but remained significant upon adjustment for BMI (Table 4).
Adjusting for smoking had a similar effect in HAPI Heart (Table 4). The association
between methylation at the CPT1A locus and circulating adiponectin in the meta-analysis of
all 2300 participants was highly significant: P=4.4x10−16.
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Among genes harboring known sequence variants associated with circulating adiponectin,
none contained epigenome-wide significant (FDR < 0.20) methylation hits. The top locus
among such candidate genes (regression coefficient (SE)= −0.003 (0.0008), P=0.003) maps
to CDH13 on chromosome 16.
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Discussion
The evidence in support of epigenetic regulation of complex traits such as plasma
adiponectin is growing at a fast pace. However, prior to our study, investigations of
epigenetic determinants of adipocytokines were limited to candidate gene analyses, usually
involving the adiponectin gene itself (ADIPOQ) or its receptor (ADIPOR1), or other
candidate genes such as CDH13 (19–21). The advent of high-resolution arrays enabled
epigenome-wide profiling and discovery of novel loci such as the one we identified and
successfully replicated in CPT1A, UFM1, and RNF145. It is highly likely that the observed
association between all three loci and adiponectin levels are related to obesity, as evidenced
by the results of our sensitivity analyses.
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The differentially methylated locus identified and replicated in our study is located in the
first intron of CPT1A, which encodes carnitine palmitoyltransferase 1A, the rate-limiting
enzyme for mitochondrial fatty acid oxidation. Prior studies—including several from
GOLDN—have linked methylation of CPT1A to 1) reduced expression of CPT1A and 2)
obesity indices, plasma triglycerides, very low-density lipoprotein cholesterol, and metabolic
syndrome, highlighting the biological relevance of the observed association (6, 13, 22).
Specifically, the study linking CPT1A methylation to circulating lipids also provided
functional annotation data, illustrating the regulatory potential of the top CpG site: in
addition to several transcription factor binding sites, our top locus is also adjacent
(upstream) to an active promoter region, and overlaps an H3K27Ac histone mark (6).
Interestingly, prior analyses of the GOLDN data (6) do not report significant sequence
variant effects (methylation quantitative trait loci) in that region. Other groups have found
hepatic expression of CPT1A to be correlated with the amount of liver fat, and the
correlation decreased when adjusted for BMI (23). In the GOLDN and HAPI studies,
adjustment for BMI similarly, albeit incompletely, attenuated the estimate of CPT1A effect.
In contrast, the association between CPT1A and plasma adiponectin was not observed at all
among Black participants from BHS, and was eliminated completely upon adjustment for
BMI among White participants. Considering the small size of the Black sample, this may
represent limitations of statistical power rather than true effect modification by race; in fact,
CPT1A methylation was confirmed to be associated with BMI in a much larger African
American sample from the Artherosclerosis Risk in Communities study (13).
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Previously published evidence shows that the relationship between epigenomic variation,
obesity, and adiponectin is likely to be complex and multidirectional. For example, in a
recent animal study, obesity has been shown to mediate insulin resistance by inducing
hypermethylation of the adiponectin gene (4), while in a small-scale human trial both
obesity and insulin resistance actually diminished methylation of both leptin and adiponectin
promoters (24). It is noteworthy that methylation of ADIPOQ or any other known
adiponectin loci was associated with neither obesity (13) nor insulin resistance (25) nor
adiponectin in GOLDN, suggesting alternative pathways of epigenetic regulation.
In addition to the CPT1A locus, we have identified and replicated associations with CpG
sites located in UFM1 and RNF145. The cg19750657 locus is located in the 3’ UTR region
of UFM1 (ubiquitin-fold modifier 1), which encodes a highly conserved posttranslational
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modifier involved in endoplasmic reticulum functions and other cellular processes (26).
Specifically, it is highly expressed in pancreatic islets and upregulated in type 2 diabetes,
representing a protective response to endoplasmic reticulum stress (27). The cg19750657
site in particular has been shown to be hypermethylated in adipose tissue in the setting of
type 2 diabetes (28), consistent with our observed inverse association with plasma
adiponectin. Although its location in the 3’ UTR region (Figure 2) makes it an unlikely
candidate for influencing expression, prior studies show that methylation of the untranslated
regions may exert other forms of epigenetic control, notably transcription elongation (29).
Related to the ubiquitin pathway represented by our UFM1 finding is the ring zinger protein
encoded by RNF145, which includes the other replicated methylation locus. Namely, it
regulates an ubiquitin-cycling node in the oxidative burst response and is involved in
endopasmic reticulum-associated degradation (30). Notably, methylation of cg26403843 in
RNF145 has been previously linked to BMI and waist circumference in several diverse
populations (31, 32). Additionally, the cg26403843 site colocalizes with an H3K27Ac
histone mark in immune cells from the ENCODE data, suggesting an active regulatory
element (Figure 3). However, despite successful replication across cohorts, these findings
need to be interpreted with caution because the strength of the association was attenuated
upon adjustment for either BMI or smoking + alcohol, indicating potential influence of
known epigenetic confounders.
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Like most population-based studies of epigenetic patterns published to date, our study is
cross-sectional and restricted to blood samples. We argue that the use of CD4+ T cells
(discovery cohort) as well as whole blood samples (replication) represent a strength rather
than a weakness of our study, as these are easily accessible tissues with high translational
potential. Importantly, a previous study has reported high correlation of DNA methylation
levels at biologically relevant (with regard to leptin and adiponectin regulation) CpGs
between blood and adipose tissue (both visceral and subcutaneous), corroborating the
validity of our strategy (33). To account for the dynamic nature of epigenetic processes, our
findings would best be followed up by investigating links between gene methylation/
expression and adipocytokines in a longitudinal setting to control for reverse causation.
Additionally, future studies would benefit from attempting validation of our preliminary
findings of other adiponectin-related methylation loci, furthering current understanding of
the genetic architecture of circulating adiponectin.
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In summary, we have conducted the first epigenome-wide study of circulating adiponectin
levels. We have shown that methylation of a CpG site in CPT1A is associated with
circulating adiponectin levels, likely in an obesity-dependent manner, in three populationbased adult cohorts of European descent. Our findings enhance current understanding of
genetic architecture of plasma adiponectin levels and lay the groundwork for testing CPT1A
methylation as a novel pleiotropic marker of chronic disease risk.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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•

We conducted the first epigenome-wide study of plasma adiponectin (total
N=2,300)

•

34 methylation loci suggested association (FDR <0.2) with plasma
adiponectin in the GOLDN cohort

•

Associations with loci in CPT1A, UFM1, and RNF145 were replicated in
individuals of European but not African descent; adjustment for BMI
attenuated the observed associations
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Figure 1. Epigenome-wide associations of CpG methylation with plasma adiponectin in GOLDN
(n=991)

Author Manuscript

Manhattan plot of epigenome-wide results of testing for association between methylation at
368,051 CpG sites and plasma adiponectin. The X-axis displays the chromosome on which
the site is located, the Y-axes display −log10(P-value). The red horizontal line indicates the
threshold for epigenome-wide statistical significance after a Bonferroni correction (P-value
< 0.05/368,051= 1.4x10−7).
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Figure 2. ENCODE/Roadmap Epigenomics Project annotation of the genomic region containing
the UFM1 methylation locus
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Functional annotation of the genomic region containing the UFM1 (Figure 2) and RNF145
(Figure 3) methylation loci on chromosomes 13 and 5 respectively, generated using data
from the ENCODE/Roadmap Epigenomics Project. Functional features are listed on the Yaxis, while the X-axis represents the genomic position (hg19, Human Genome Build 37).
Notable features include (from top to bottom): CpG islands, chromatin state across tissues
physiologically relevant to adiponectin regulation (adipose and hepatic), known genes,
layered H3K27Ac marks commonly found near active regulatory elements. The location of
the CpG is marked by the faint blue vertical line.
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Figure 3. ENCODE/Roadmap Epigenomics Project annotation of the genomic region containing
the RNF145 methylation locus
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Functional annotation of the genomic region containing the UFM1 (Figure 2) and RNF145
(Figure 3) methylation loci on chromosomes 13 and 5 respectively, generated using data
from the ENCODE/Roadmap Epigenomics Project. Functional features are listed on the Yaxis, while the X-axis represents the genomic position (hg19, Human Genome Build 37).
Notable features include (from top to bottom): CpG islands, chromatin state across tissues
physiologically relevant to adiponectin regulation (adipose and hepatic), known genes,
layered H3K27Ac marks commonly found near active regulatory elements. The location of
the CpG is marked by the faint blue vertical line.
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Demographic and clinical characteristics of the study populations.

Age, years*

GOLDN (n=991)

HAPI (n=474)

BHS White (n=592)

BHS Black (n=243)

49 ± 16

44 ± 14

43 ± 5

43 ± 5

Sex, n female (%)

518 (52)

221 (47)

318 (54)

157 (65)

Plasma adiponectin, μg/dL

8.3 ± 4.7

11.3 ± 5.9

8.9 ± 4.2

7.5 ± 4.0

Current smokers, n (%)
Body mass index,

kg/m2

73 (7)

51 (11)

151 (26)

74 (30)

28.3 ± 5.7

26.6 ± 4.4

28.6 ± 6.3

31.6 ± 8.3

*

Values for continuous variables are shown as mean or median ± SE.
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cg25649039
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6
19
6
19
11
3

cg18758976

cg18244544

cg26894079

cg18098839

cg06710295

cg11552078

8

cg26985149

cg16597079

2
17

cg18810022

3

19

cg19393762

cg26797723

11

cg05931265

2

20

cg05358404

cg05879734

5

cg19828789

5

17

cg14266156

13

11

cg22964469

cg19750657

9

cg24787076

11

cg21212076

Chromosome

cg00574958

Marker

--

--

North shore

--

South shore

--

Island

Island

--

Island

--

--

North shore

--

--

--

South shore

Island

--

--

--

--

North shore

Region

−0.008 ± 0.002
−0.01 ± 0.002
0.004 ± 0.0009
−0.008 ± 0.002

PRKCA
RPL37
UFM1

0.005 ± 0.001
0.002 ± 0.0005
0.006 ± 0.001
0.005 ± 0.001
0.007 ± 0.002
0.002 ± 0.0004
0.01 ± 0.002
0.004 ± 0.001

MTSS1
TRERF1
TIMM50
SYNJ2
ZNF224
ASAM
GOLIM4

0.008 ± 0.002

Intergenic

Intergenic

−0.004 ± 0.001

−0.009 ± 0.002

TNNT1
GPR114

WNT5A

0.006 ± 0.001

UBASH3B

0.003 ± 0.0007

0.02 ± 0.003

RTEL1

Intergenic

−0.008 ± 0.002

Intergenic

0.007 ± 0.001

0.007 ± 0.001

SORL1
Intergenic

0.01 ± 0.001
−0.02 ± 0.003

CPT1A

FAM166B

Regression Coefficient ± SE

Gene

GOLDN

0.0008 ± 0.002

0.0001 ± 0.001
−0.0001 ± 0.001
0.001 ± 0.002
−0.001 ± 0.001
0.0003 ± 0.001
0.006 ± 0.003
0.005 ± 0.002

7.8x10−6
7.9x10−6
7.9x10−6
7.9x10−6
8.9x10−6
9.0x10−6
9.7x10−6

6.3x10−6

−0.002 ± 0.002

0.0005 ± 0.0006

6.1x10−6

7.4x10−6

0.002 ± 0.001

5.2x10−6

5.4x10−6

0.002 ± 0.001
−0.01 ± 0.003

4.7x10−6

−0.002 ± 0.002

−0.0004 ± 0.002

3.0x10−6

4.6x10−6

0.006 ± 0.004

2.9x10−6

−0.002 ± 0.002

0.0003 ± 0.002

2.8x10−6

−0.0004 ± 0.002

−0.0004 ± 0.002

1.6x10−6

4.1x10−6

0.0009 ± 0.002

8.8x10−7

3.6x10−6

0.006 ± 0.001
−0.002 ± 0.004

7.8x10−7

Regression Coefficient ± SE

3.4x10−13

P-value

BHS White

0.005

0.02

0.70

0.36

0.62

0.92

0.89

0.34

0.60

0.46

0.12

0.0002

0.09

0.47

0.81

0.34

0.86

0.21

0.84

0.78

0.56

0.61

0.0005

P-value

0.002 ± 0.003

0.006 ± 0.004

0.0009 ± 0.001

−0.0003 ± 0.002

−0.006 ± 0.003

0.002 ± 0.002

0.0004 ± 0.001

0.0002 ± 0.003

−0.0002 ± 0.002

−0.003 ± 0.001

0.005 ± 0.002

0.003 ± 0.006

0.003 ± 0.002

−0.004 ± 0.003

−0.0003 ± 0.003

−0.0002 ± 0.003

−0.006 ± 0.003

−0.0002 ± 0.005

−0.0008 ± 0.002

−0.002 ± 0.003

0.004 ± 0.002

0.001 ± 0.005

0.0006 ± 0.003

Regression Coefficient ± SE

BHS Black

0.44

0.14

0.36

0.88

0.03

0.23

0.74

0.94

0.93

0.008

0.02

0.66

0.09

0.24

0.89

0.95

0.05

0.96

0.66

0.56

0.01

0.85

0.18

P-value

association from the replication analysis** in BHS (White n=592, Black n=243). Associations with CpGs that successfully replicated in at least one BHS
racial group (P<0.05/34= 0.001) are in bold.

Top CpG methylation sites associated* with plasma adiponectin in GOLDN (n=991) (false discovery rate <0.2) and corresponding estimates of
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15
15
3
14
5
12
5
1
16
1
7

cg00325866

cg15183258

cg14652230

cg09251317

cg26403843

cg08775774

cg17593721

cg23923820

cg05466767

cg19595760

cg14584616

North shelf

South shelf

North shelf

South shore

South shore

--

North shelf

--

North shore

--

North shore

Region

−0.008 ± 0.002
0.002 ± 0.0004
0.003 ± 0.0007
−0.01 ± 0.002
0.005 ± 0.001
0.009 ± 0.002
−0.008 ± 0.002

RNF145

CCDC62
HSD17B4
PKLR
FTSJD1
MAN1C1
HEATR2

−0.02 ± 0.004
0.002 ± 0.0005

MGA
NICN1
0.008 ± 0.002

0.001 ± 0.0002

C2CD4A

Intergenic

Regression Coefficient ± SE

Gene

−0.001 ± 0.003
−0.0006 ± 0.0008
−0.0004 ± 0.002
−0.02 ± 0.004
−0.0005 ± 0.0006
0.0004 ± 0.001
−0.0004 ± 0.002
−0.0009 ± 0.0007
0.001 ± 0.002
0.0001 ± 0.001

1.1x10−5
1.4x10−5
1.5x10−5
1.5x10−5
1.5x10−5
1.5x10−5
1.6x10−5
1.8x10−5
1.8x10−5

−0.0004 ± 0.0005

9.9x10−6
1.0x10−5

Regression Coefficient ± SE

P-value

0.91

0.63

0.18

0.85

0.73

0.47

0.0004

0.80

0.46

0.62

0.45

P-value

−0.001 ± 0.002

−0.0008 ± 0.003

−0.002 ± 0.001

−0.003 ± 0.004

−0.003 ± 0.002

−0.0002 ± 0.0008

−0.01 ± 0.006

0.007 ± 0.003

0.001 ± 0.001

0.001 ± 0.004

−0.0006 ± 0.0007

Regression Coefficient ± SE

BHS Black

0.58

0.82

0.58

0.41

0.09

0.83

0.04

0.01

0.41

0.77

0.37

P-value

Association estimates in BHS were obtained from linear mixed models with ln-transformed adiponectin as a predictor and methylation β score as the outcome, adjusted for age, sex, white blood cell
counts (fixed effects) and batch (random effect).

**

Association estimates in GOLDN were obtained from linear mixed models with ln-transformed adiponectin as a predictor and methylation β score as the outcome, adjusted for age, sex, study site, T-cell
purity principal components (fixed effects) and family relatedness (random effect).

*
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5

cg24787076

North shore

North shore

Region

Regression Coefficient ± SE
0.008 ± 0.001
0.005 ± 0.0009

Gene

CPT1A
RPL37

2.3x10−7

1.9x10−8

P-value

Association estimates were obtained from linear mixed models with ln-transformed adiponectin as a predictor and methylation β score as the outcome, adjusted for age, sex, BMI, study site, T-cell purity
principal components (fixed effects) and family relatedness (random effect).

*

11

Chromosome

cg00574958

Marker

Top CpG methylation sites associated* with plasma adiponectin (false discovery rate <0.2) in the discovery population (n=991), adjusted for body mass
index.
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*

592

243

BHS (White)

BHS (Black)

0.003 ± 0.002

0.006 ± 0.002

0.88 ± 0.26

0.01 ± 0.001

Regression Coefficient ± SE

0.18

0.0005
0.0006 ± 0.003

0.002 ± 0.002

0.61 ± 0.28

0.008 ± 0.001

3.4x10−13
0.0009

Regression Coefficient ± SE

P-value

Basic model* + BMI

0.79

0.14

0.03

1.9x10−8

P-value

0.0008 ± 0.003

0.002 ± 0.002

0.60 ± 0.27

0.01 ± 0.001

Regression Coefficient ± SE

0.74

0.15

0.03

7.4x10−14

P-value

Basic model* + smoking + alcohol**

Alcohol intake data was not available in HAPI Heart but is likely to be minimal due to religious restrictions; therefore, the association estimates for HAPI Heart in this column are derived from basic
model + smoking.

**

Basic model refers to a linear mixed model with ln-transformed adiponectin as a predictor and methylation β score as the outcome, adjusted for age, sex, technical covariates (in GOLDN: study site and Tcell purity principal components; in HAPI Heart: batch; in BHS: white blood cell counts and batch), and family relatedness (only in GOLDN and HAPI Heart).

474

991

GOLDN

HAPI Heart

N

Cohort

Basic model*

Associations between the methylation of the cg00574958 locus in CPT1A in the discovery and replication cohorts.
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